1. Post Genomics of pathogenic bacteria 
2. The interaction between bacteria and hosts, immunology, and the development of vaccines
3. The research and development of antibiotics  and the resistance mechanism and the mechanism of action of drugs. 

2005/10-2010/8： The Johns Hopkins University School of Medicine , Posdoctoral fellow.

2002/08-2005/07：Institute of Medicinal Biotechnology,
The Chinese Academy of Medical Sciences &The Peking Union Medical College (PUMC & CAMS), Ph.D. 

1999/09-2002/07：College of Life Science, Capital Normal University, M.S.

1995/09-1999/07：College of Life Science, Capital Normal University, B.S.

Main 1st autor and corresponding author publications:

[1] Islam M, Hameed A, Mugweru J,  Chhotaray C,  Wang C,  Tan Y,  Liu J, Li X, Tan S, Ojima I,  Yew W, Zhang T*. Drug Resistance Mechanisms and Novel Drug Targets for Tuberculosis Therapy. J Genet Genomics. 2016. (on line). 

[2] Guo J, Wang C, Han Y, Liu Z, Wu T, Liu Y, Liu Y, Tan Y, Cai X, Cao Y, Wang B, Zhang B, Liu C, Tan S and Zhang T*.Identification of Lysine Acetylation in Mycobacterium abscessus Using LC-MS/MS after Immunoprecipitation. J Proteome Res 2016. 15(8):2567-2578. (DOI: 10.1021/acs.jproteome.6b00116).

[3] Tan S*, Rao Y, Guo J, Tan Y, Cai X, Kuang H, Li Y, Liu W, Mugweru J, Wang B, Cao Y, Wang C, Zhang Y, Zhang T*. The Influence of Pyrazinamide Monoresistance on Treatment Outcomes in Tuberculosis Patients from Southern China. J Tuberculosis Res. 2016. 4:9-17.

[4] Makafe G, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire M, Cai X, Liu Ti, Wang B, Pang W, Tan S, ZhangB, Yew W, Lamichhane G, Guo J, Zhang T*. Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016.60(5):3202-3206.

[5] Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S*, Zhang T*. Pyrazinamide resistance in Mycobacterium tuberculosis: review and update. Adv Med Sci. 2016. 61(1):63-71. 

[6] Tang J, Wang B, Wu T, Wan J, Tu Z, Njire M, Wan B, Franzblauc SG, Zhang T*, Lu X*, Ding K*. Design, synthesis and biological evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as novel anti-tubercular agents. ACS Med Chem Lett. 2015. 6:814-818.

[7] Liu T, Wang B, Guo J, Zhou Y, Julius M, Njire M, Cao Y, Wu T, Liu Z, Wang C, Xu Y, Zhang T*. Role of folp1 and folp2 genes in the action of sulfamethoxazole and trimethoprim against mycobacteria. J Microbiol Biotechnol. 2015. 25(9):1559-1567.

[8] Yang F, Njire M, Liu J, Wu T, Wang B, Liu T, Cao Y, Liu Z, Wan J, Tu Z, Tan Y, Tan S, Zhang T*. Engineering more stable, selectable marker-free autoluminescent mycobacteria by one step. PLoS One. 2015. 10(1):e0119341.

[9] Yang F, Tan YJ, Liu J, Liu TZ, Wang BX, Cao YY, Qu Y, Lithgow T, Tan SY, Zhang T*. Efficient construction of unmarked recombinant mycobacteria using an improved system. J Microbiol Methods. 2014. 103:29-36

[10] Tan YJ, Hu ZQ, Zhang T *, Cai XS, Kuang HB, Liu YW, Chen JY, Yang F, Zhang K, Tan SY*, Zhao YL. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014. 52(1):291-297.

[11] Tan S*, Sun D, Zhang T, Li Y, Cao Y, Njire M, Wang C, Zhang T*. Risk factors for hemoptysis in pulmonary tuberculosis patients from southern China: a retrospective study. J Tuberculosis Res. 2014. 2:173-180.

[12] Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL*. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection. PLoS Negl Trop Dis. 2013.7(12):e2598.

[13] Chen C, Lu M, Liu Z, Wan J, Tu Z, Zhang T*, Yan M*. Synthesis and evaluation of 2-amino-4h-pyran-3-carbonitrile derivatives as antitubercular agents. Open J Med Chemi. 2013. 3: 128-135.

[14] Zhang T, Li SY, Nuermberger EL*. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One. 2012. 7:e29774.

[15] Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL*. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011. 184:732-737.

[16] Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, Nuermberger EL*. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother. 2011. 55:56-61

[17] Zhang T, Bishai WR, Grosset JH, Nuermberger EL*. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother. 2010. 54(7): 2806-2813.

[18] Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL*. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2009. 180: 1151-1157.

[19] Zhang T, Wang L，Xu G，Chen Y，Zhang Y，Li Y*. Disruption of ste23 gene affects composition profile and bioactivity of exopolysaccharide produced by Streptomyces sp. 139. Lett App Microbiol. 2006, 42(2):132-137.

[20] Zhang T, Wang L，Xu G，Chen Y，Zhang Y，Li Y*. Disruption of the ste22 Gene Encoding a Glycosyltransferase and Its Function in Biosynthesis of Ebosin in Streptomyces sp. 139. Curr Microbiol.2006, 52(1):55-59.

美国专利：

Eric Nuermberger, Tianyu Zhang, Jacques Grosset. Autoluminescent mycobacterial reporter strains，2011, patent number: (61/367,475).

PCT：

[1] 陆小云，汤健，丁克，张天宇，涂正超，伍甜，万军庭，曹元元。吡唑并[1,5-a]吡啶类化合物及其应用，2015，PCT (CN2015/086852)。

[2] 张天宇，刘志永。一种可投送自主发光元件的分枝杆菌噬菌体及其应用，2016，PCT（CN2016/081202）

中国专利：
[1] 张天宇，杨峰，刘佳。整合质粒pOPHI及无抗性筛选标记的自主发光分枝杆菌（2012）, 专利号：ZL 201210183007.2。授权证书号：1296049, 授权公告日：2013.10.30。
[2] 张天宇，杨峰，邹文英。一种用于高效构建无抗性标记重组分枝杆菌的抗性表达盒（2013）,专利号：ZL 201310386264.0。授权证书号：1799902, 授权公告日：2015.09.23。
[3] 朱强，张天宇，刘兰英，鲁明辉，毛婷婷，黄金波。吲哚[3,2-c]喹啉类化合物或其药学上可接受的盐及其制备方法和应用（2013），ZL 201310385431.X。授权证书号：2017232, 授权公告日：2016-04-06。

[4] 丁克，陆小云，张天宇，汤健，鲁明辉，李宇鹏，张章，梁镇兴，钱政江。N-4-三氟甲基苯基水杨酰胺衍生物的制备方法和应用（2014），专利申请号：201410073672.5。

[5] 陆小云，汤健，丁克，张天宇，涂正超，伍甜，万军庭，曹元元。吡唑并[1,5-a]吡啶类化合物及其应用(2014)，专利申请号：201410562805.5 [优先权专利号更改为2015104607516]。

[6] 张天宇，曹元元，伍甜，谭守勇，谭耀驹，蔡杏珊，刘春平。构建无选择标记的自主发光脓肿分枝杆菌的方法及建立相应体外高通量筛药模型(2015)，专利申请号：201510104936.3。

[7] 张天宇，刘志永。一种可投送自主发光元件的分枝杆菌噬菌体及其应用(2016)，专利申请号：201610127984.9。

[8] 鞠建华，马俊英，张天宇，刘志永。一种海洋链霉菌及其环肽化合物在制备抗结核分分枝杆菌药物中的应用（2016），专利申请号：201610255638.9。

[9] 张天宇，Moses M Njire，王邦兴，刘志永，韩轶，刘燕，刘洋。一种检测结核分支杆菌耐药性的DNA标记物及其应用(2016)，专利申请号：201610564946.X。

[10] 涂正超（475345840 （美国护照），朱强，张天宇，黄金波，徐晓冰，万军庭，黎敏科，李登科，周亚丽，刘志永，王邦兴，米琦.托特雷拉。吲哚-2-酮-3-螺噻嗪酮或噻唑酮化合物及其应用(2016)，专利申请号：2016106571617。 (申请提交日：2016/8/11)

[11] 张天宇, 马格文如.朱丽俄斯，刘燕，王邦兴，曹元元，黄少波，玛卡芬.盖乐, 张洋，郭锦涛，柴然吉比.筹多拉瑞，刘洋。一种硫链丝菌素-庆大霉素抗性基因体系及还有其的抗性表达盒和重组质粒（2016），专利申请号：2016101801161450。 (申请提交日：2016/10/18)

2011.05  Progress in Establishing Mouse Model of Latent Tuberculosis Infection(LBTI) and the Short-course Chemotherapy of LTBI with TMC-207 was selected as an oral presentation  at The 2011 Meeting of the American Thoracic Society (ATS ).
 
2010.09 The work about testing drug activity using bioluminescent Mycobacterium ulcerans both in vitro and in vivo was presented at 49th
Interscience Conference on Antimicrobial Agents and Chemotherapy (IACCA) and was submitted as Press Summary. 

2010.04 Had the meeting about tuberculosis advocated by New York Academy of Sciences. 

2009.05 Progress in Establishing Mouse Model of Latent Tuberculosis Infection(LBTI) and the Short-course Chemotherapy of LTBI with rifapentine was presented orally  at The 2009 Meeting of the American Thoracic Society (ATS ).  This evoked a strong reaction.
 
2009.01 Progress in Establishing Mouse Model of Latent Tuberculosis Infection(LBTI) and the Short-course Chemotherapy of LTBI with rifapentine 
was presented as a poster at the keystone meeting （Tuberculosis: Biology, Pathology and Therapy）.

2004.07 The study of the product of the ste24 gene which related to the biosynthesis of Ebosin was presented as a poster at the 10th SCBA INTERNATIONAL SYMPOSIUM